PRFXNasdaqPharmaceutical PreparationsFiscal year ends December 31

PRF Technologies Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026

$0.71−0.07 (-8.88%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

PRF Technologies Ltd. cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Stock-Based Compensation	0.45	0.31	0.80	1.39	0.81	0.04	0.09	–
Operating Cash Flow	-3.96	-13	-6.68	-6.46	-6.55	-2.56	-0.61	-0.64
Capital Expenditures	0.00	-0.01	-0.01	-0.01	-0.05	-0.01	0	–
Purchase of Investments	-1.00	0	-1.00	-6.00	0	0	–	–
Sale & Maturity of Investments	–	0	7.00	–	–	–	–	–
Investing Cash Flow	-0.98	-0.01	5.99	-6.01	-0.05	-0.01	0	–
Stock Issued	4.00	1.35	0	0	6.00	0	0	–
Financing Cash Flow	3.82	8.86	4.62	0	7.48	17	1.51	0.49
Foreign Exchange Rate Adjustments	0.00	0.01	0.00	0	0	0.00	0.00	0.00
Net Change in Cash	-1.12	-3.77	3.93	-12	0.88	–	–	–
Free Cash Flow	-3.96	-13	-6.69	-6.47	-6.60	-2.57	-0.61	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: -311.8%
Operating margin: -30129.4%
Net margin: -29541.2%
Return on equity, FY2025: -96.9%

Financial strength

Current ratio: 5.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 363.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –